SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Bayer345 enrolled

Overview

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

Study Type

OBSERVATIONAL

Enrollment

345

Conditions

Chronic Bronchitis

Interventions

Moxifloxacin (Avelox, BAY12-8039)DRUG

Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Acute exacerbation of chronic bronchitis from Anthonisen type I or II * FEV1 of \< 50 % * Patient must be ensured in the statutory health insurance * Further contraindications of the prescribed pharmaceutical products must be considered Exclusion Criteria: * Patients who change from one cohort to the other

Locations (1)

Unnamed facility

Many Locations, Germany

Outcomes

Primary Outcomes

Effectiveness and tolerance of/to the different therapies

Time frame: within the first 14 days

Possible hospitalisation rate

Time frame: within the first 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.